April 23, 2015 9:31 AM | 1 min read |
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
(NYSE: ABBV) reported stronger-than-expected earnings for the first quarter and lifted its full-year earnings forecast.The company now expects FY15 earnings of $4.10 to $4.30 per share, versus its earlier forecast of $4.05 to $4.25 per share.The North Chicago, Illinois-based company reported a quarterly profit of $1.02 billion, or $0.63 per share, versus a year-ago profit of $980 million, or $0.61 per share. Excluding items, the company's climbed to $0.94 per share from $0.71 per share.Its revenue climbed 10.5 percent to $5.04 billion. However, analysts were expecting earnings of $0.85 per share on revenue of $4.98 billion.Global Humira sales climbed 18 percent.Adjusted operating margin widened to 40.1 percent in the first quarter, versus 33.9 percent in the year-ago quarter.The average estimate among 11 Estimize users was for earnings of $0.85 per share and revenue of $5.02 billion."AbbVie had an exceptional first quarter, delivering on our projection of top-tier EPS growth, as well as robust sales growth and significant margin expansion," said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. AbbVie shares rose 1.13 percent to $65.25 in pre-market trading.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.